3 Attitude of Japanese Cardiologists for the Management of Antithrombotic Therapy for Patients with Non-valvular Atrial Fibrillation(Symposium 6 (SY-06) (A) Recent Strategies for Total Management of Atrial Fibrillation,Special Program,The 72nd Annual Scie
スポンサーリンク
概要
- 論文の詳細を見る
- 社団法人日本循環器学会の論文
- 2008-03-01
著者
-
TAKENAKA Takashi
National Sapporo Hospital
-
Iwade Kazunori
National Hospital Organization Yokohama Medical Center
-
Koretsune Yukihiro
Clinical Res. Inst. National Hospital Organization Osaka National Hospital
-
J-NHOAF study
Clinical Res. Inst., National Hospital Organization, Osaka National Hospital
-
J-nhoaf Study
Clinical Res. Inst. National Hospital Organization Osaka National Hospital
-
Takenaka Takashi
National Hospital Organization Hokkaido Cancer Center
関連論文
- Effect of Celiprolol on Cardiac Hypertrophy in Hypertension
- Effect of Celiprolol on Cardiac Hypertrophy in Hypertension
- Comparison of 5-Hydroxytryptamine-Induced Contraction of Rat Pulmonary Artery to That of Aorta in Vitro
- -0341-CHANGES OF BETA-ADRENOCEPTOR/ADENYLATE CYCLASE SYSTEM IN HYPERTROPHIC HEART FROM MONOCROTALINE-TREATED RATS
- -0236-INTERACTION BETWEEN 5-HT RECEPTOR AND ALPHA-ADRENERGIC RECEPTOR IN RAT PULMONARY ARTERY AND AORTA
- ELECTROGENIC Na PUMP ACTIVITY ESTIMATED BY POTASSIUM RELAXATION IN PULMONARY ARTERIAL SMOOTH MUSCLE FROM MONOCROTALINE-TREATED RATS : Pulmonary, Peripheral, Cerebral Circulation : 53 Annual Scientific Meeting, Japanese Circulation Society
- 3 Attitude of Japanese Cardiologists for the Management of Antithrombotic Therapy for Patients with Non-valvular Atrial Fibrillation(Symposium 6 (SY-06) (A) Recent Strategies for Total Management of Atrial Fibrillation,Special Program,The 72nd Annual Scie
- Ca^-INDUCED CONTRACTRON AND HYPERREACTIVITY OF PULMONARY ARTERIAL SMOOTH MUSCLE IN MONOCROTALINE-TREATED RATS
- Prediction of thromboembolic accidents by coagulation markers in non-valvular atrial fibrillation : Prospective 5-year follow-up study in a single center
- Randomized, Multicenter, Warfarin-Controlled Phase II Study of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation